EHA 2024: Highlights in Multiple Myeloma : Episode 4

Opinion

Video

July 17, 2024

Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

EP: 1.Latest Trends and Innovations in Multiple Myeloma Management at EHA 2024

EP: 2.EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma

EP: 3.PERSEUS Trial Findings at EHA 2024

Now Viewing

EP: 4.Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

EP: 5.EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

EP: 6.EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

EP: 7.Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Video content above is prompted by the following question:

Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Testing in multiple myeloma | Image credit: angellodeco - stock.adobe.com

June 12th 2025

DVRd Improves MRD Negativity, Maintains Quality of Life in Multiple Myeloma

Pearl Steinzor

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com

June 7th 2025

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

Jared Kaltwasser

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).

May 19th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

Laura Joszt, MA

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.